Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 12178.157 | uM | inf | inf | 0.8714 | 0.8714 | 0.0000 | -0.0235 | -0.1217 | 0.5528 | |
| BT-474 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 12056.157 | uM | inf | inf | 0.8491 | 0.8491 | 0.0000 | 0.0630 | 0.0552 | 0.9748 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7833.042 | uM | inf | inf | 0.8856 | 0.8856 | 0.0000 | 0.0972 | 0.0274 | 1.0332 | |
| BT-474 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 12291.157 | uM | inf | inf | 0.6757 | 0.6757 | 0.0000 | 0.1553 | 0.1959 | 0.5161 | |
| MDA-MB-415 | HR+ | Luminal | Etoposide | TOP2 | TOP | 7512.074 | uM | inf | inf | 0.0745 | 0.0745 | 0.0000 | 0.4637 | 0.4272 | 0.9022 | |
| HCC2185 | TNBC | Luminal | Lapatinib | EGFR/HER2 | ErbB | 7464.098 | uM | inf | inf | 0.9208 | 0.9208 | 0.0000 | 0.0740 | 0.2911 | 0.6305 | |
| BT-474 | HER2amp | Luminal | GM6001 | MMP | MMP | 5905.096 | uM | inf | inf | 0.3979 | 0.3979 | 0.0000 | 0.1096 | 0.2122 | 0.9091 | |
| BT-474 | HER2amp | Luminal | Glycyl-H-1152 | ROCK2 | 12056.16 | uM | inf | inf | 0.6628 | 0.6628 | 0.0000 | 0.1074 | 0.4482 | 0.9124 | ||
| MCF7 | HR+ | Luminal | AG1024 | IGF1R | RTK | 7493.066 | uM | inf | inf | 0.9557 | 0.9557 | 0.0000 | -0.0077 | 0.2568 | 1.3293 | |
| HCC70 | TNBC | Basal A | FR180204 | ERK1/2 | MAPK | 10873.149 | uM | inf | inf | 0.7679 | 0.7679 | 0.0000 | 0.0579 | 0.5384 | 1.2562 | |
| BT-20 | TNBC | Basal A | PS-1145 | IKK | NFKB | 5904.065 | uM | inf | inf | 0.7615 | 0.7615 | 0.0000 | 0.0871 | 0.5385 | 1.1681 | |
| SUM159PT | TNBC | Basal B | Nelfinavir | 13054.174 | uM | inf | inf | 0.9613 | 0.9613 | 0.0000 | 0.0251 | 0.1450 | 3.1161 | |||
| BT-20 | TNBC | Basal A | PS-1145 | IKK | NFKB | 10385.065 | uM | inf | inf | 0.4664 | 0.4664 | 0.0000 | 0.3016 | 0.3040 | 0.6599 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 11057.145 | uM | inf | inf | 1.0062 | 1.0062 | 0.0000 | -0.0143 | -0.1841 | 3.8266 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 10518.136 | uM | inf | inf | 0.9091 | 0.9091 | 0.0000 | 0.0220 | 0.1805 | 1.2490 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7876.042 | uM | inf | inf | 0.9178 | 0.9178 | 0.0000 | -0.0251 | 0.2224 | 1.0958 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7811.018 | uM | inf | inf | 0.6946 | 0.6946 | 0.0000 | 0.1308 | -0.0060 | 0.4694 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7812.042 | uM | inf | inf | 0.5614 | 0.5614 | 0.0000 | 0.0267 | 0.3674 | 0.9722 | |
| BT-474 | HER2amp | Luminal | JNK-IN-5A | JNK | JNK | 12178.144 | uM | inf | inf | 0.6802 | 0.6802 | 0.0000 | 0.1793 | -0.0043 | 0.7891 | |
| MCF 10F | NM | - | Cetuximab | EGFR | ErbB | 7872.042 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0054 | -0.0002 | 1.3632 | |
| MDA-MB-175-VII | HR+ | Luminal | PD184352 | MEK | MAPK | 10818.155 | uM | inf | inf | 0.4077 | 0.4077 | 0.0000 | 0.1609 | 0.5531 | 0.6048 | |
| BT-474 | HER2amp | Luminal | JNK-IN-5A | JNK | JNK | 12056.144 | uM | inf | inf | 0.8442 | 0.8442 | 0.0000 | 0.0965 | 0.2228 | 0.9738 | |
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 9146.122 | uM | inf | inf | 0.9694 | 0.9694 | 0.0000 | -0.0404 | -1.9847 | 1.3408 | |
| MDA-MB-415 | HR+ | Luminal | Nutlin 3a | MDM2 | MDM2 | 7510.066 | uM | inf | inf | 0.3525 | 0.3525 | 0.0000 | 0.2751 | 0.3310 | 0.9189 | |
| BT-474 | HER2amp | Luminal | L-779450 | BRAF | MAPK | 12291.166 | uM | inf | inf | 0.1392 | 0.1392 | 0.0000 | 0.2732 | 0.4769 | 0.5962 |